Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.67 |
| ▸ | CES1 | P23141 | 6/20 | 0.59 |
| ▸ | CES2 | O00748 | 5/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014656 | 0.93 | FAAH (0.76) | FAAHCES1CES2ALDH1A1HSD17B10 | |
| SCHEMBL1088961 | 0.91 | FAAH (0.79) | FAAHCES1CES2ALDH1A1HSD17B10 | |
| SCHEMBL7752209 | 0.91 | FAAH (0.79) | FAAHCES1CES2ALDH1A1HSD17B10 | |
| SCHEMBL1480610 | 0.91 | FAAH (0.79) | FAAHCES1CES2ALDH1A1HSD17B10 | |
| SCHEMBL7751187 | 0.91 | FAAH (0.79) | FAAHCES1CES2ALDH1A1HSD17B10 | |
| SCHEMBL7640125 | 0.91 | FAAH (0.79) | FAAHCES1CES2ALDH1A1HSD17B10 | |
| SCHEMBL18101453 | 0.90 | FAAH (0.60) | FAAHCES1CES2ALDH1A1LMNA | |
| SCHEMBL10704882 | 0.88 | FAAH (0.69) | FAAHCES1CES2ALDH1A1LMNA | |
| SCHEMBL28151009 | 0.86 | CES1 (0.54) | FAAHCES1CES2CA1ALDH1A1 | |
| SCHEMBL112407 | 0.85 | CES2 (0.55) | FAAHCES1CES2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239154-A1 | PYRUVATE AND RELATED ALPHA-KETO CARBOXYLATES AS NOVEL ADJUVANTS IN THE TREATMENT OF POST TOOTH WHITENING SENSITIVITY AND THE TISSUE PROTECTIVE EFFECT OF PYRUVATE ON THE ORAL SOFT TISSUE | RUSZNAK ZOLTAN (US) | 2017-08-24 | — | — | US | claimed |
| US-9487602-B2 | Furan based resin, process for the preparation thereof, and use of the compound | DSM IP ASSETS B.V. (NL) | 2016-11-08 | — | — | US | claimed |
| CN-103342656-B | Synthesis method of Telaprevir intermediate | SUZHOU UUGENE BIOPHARMA CO LTD | 2015-04-08 | — | — | CN | claimed |
| CN-103342656-A | Synthesis method of Telaprevir intermediate | SUZHOU UUGENE BIOPHARMA CO LTD | 2013-10-09 | — | — | CN | claimed |
| US-20130109822-A1 | FURAN BASED RESIN, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THE COMPOUND | DSM IP ASSETS B.V. (NL) | 2013-05-02 | — | — | US | claimed |
| US-20110306735-A1 | PROCESS FOR THE PREPARATION OF A HYDROXY-AROMATIC RESIN; HYDROXY-AROMATIC RESIN, AND MODIFICATION THEREOF | DSM IP ASSETS B.V. (NL) | 2011-12-15 | — | — | US | claimed |
| US-20110021740-A1 | FURAN BASED RESIN, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THE COMPOUND | DSM IP ASSETS B.V. (NL) | 2011-01-27 | — | — | US | claimed |
| EP-2222656-A1 | FURAN BASED RESIN, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THE COMPOUND | DSM IP Assets B.V. (NL) | 2010-09-01 | — | — | EP | claimed |
| US-20090203851-A1 | Process for the Preparation of a Hydroxy-Aromatic Resin: Hydroxy-Aromatic Resin, and Modification Thereof | DSM IP ASSETS B.V. (NL) | 2009-08-13 | — | — | US | claimed |
| WO-2009077587-A1 | FURAN BASED RESIN, PROCESS FOR THE PREPARATION THEREOF, AND USE OF THE COMPOUND | DSM IP ASSETS B.V. (NL) | 2009-06-25 | — | — | WO | claimed |
| US-20040110833-A1 | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2004-06-10 | — | — | US | claimed |
| EP-1379230-A1 | METHOD OF USING PYRUVATE AND/OR ITS DERIVATIVES FOR THE TREATMENT OF CYTOKINE-MEDIATED INFLAMMATORY CONDITIONS | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | claimed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | claimed |
| US-20030216470-A1 | Method for treating ileus | CRITICAL THERAPEUTICS, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| WO-2003088956-A1 | METHOD FOR TREATING ILEUS WITH AN ALPHA -KETOALKANOIC ACID OR - ESTER OR - AMIDE | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030073743-A1 | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion | XANTHUS LIFE SCIENCES, INC. (CA) | 2003-04-17 | — | — | US | claimed |
| WO-2002074301-A1 | METHOD OF USING PYRUVATE AND/OR ITS DERIVATIVES FOR THE TREATMENT OF CYTOKINE-MEDIATED INFLAMMATORY CONDITIONS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-26 | — | — | WO | claimed |
| EP-1233767-A1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | Xanthus Life Sciences, Inc. (CA) | 2002-08-28 | — | — | EP | claimed |
| WO-2001024793-A1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES, INC. (CA) | 2001-04-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232884-A1 | New pharmaceutical formulation | LIPA, CEL, LDHA | FAAH 88/4885CES1 890/4885CES2 2709/4885 |
| US-20040110833-A1 | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions | HMGB1, HMGB2, HMGB3 | FAAH 589/4885CES1 622/4885CES2 4394/4885 |
| US-20090203851-A1 | Process for the Preparation of a Hydroxy-Aromatic Resin: Hydroxy-Aromatic Resin, and Modification Thereof | HRH3, HRH1, C9 | FAAH 508/4885CES1 2109/4885CES2 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.